Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

489.800
-7.400-1.49%
Volume:588.67K
Turnover:287.22M
Market Cap:117.06B
PE:-253.52
High:504.500
Open:490.000
Low:478.000
Close:497.200
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.79
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.932
ROE:2.92%
ROA:0.03%
PB:18.81
PE(LYR):-253.52
PS:48.13

Loading ...

SKB BIO Shares Surge Over 5% in Morning Session on Merck's TROP2 ADC Therapy Phase 3 Success

Stock News
·
May 19

Sichuan Kelun-Biotech Biopharmaceutical Receives NMPA Approval For IND Application For SKB118 (CR-001)

Reuters
·
May 13

Sichuan Kelun-Biotech Wins China IND Nod for Cancer Therapy

MT Newswires Live
·
May 13

SKB BIO Receives NMPA Approval for Investigational New Drug Application of SKB118

Stock News
·
May 13

SKB BIO Secures NMPA Green Light for PD-1/VEGF Bispecific Antibody SKB118; Crescent Biopharma Collaboration Advances Global Development

Bulletin Express
·
May 13

Kelun-Biotech says China regulator clears SKB118 clinical trial application

Reuters
·
May 13

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Receives Nmpa Approval for Ind Application for Skb118 (Cr-001) for Advanced Solid Tumors

THOMSON REUTERS
·
May 13

SKB Biopharma's Application for New Indication of Tumor Drug Accepted in China

MT Newswires Live
·
May 08

the Snda for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Pembrolizumab as First‑Line Treatment for Pd-L1-Positive Nsclc Accepted for Review by Nmpa

THOMSON REUTERS
·
May 08

SKB BIO's Core TROP2 ADC Therapy Sac-TMT Gains NMPA Acceptance for New Indication Application

Stock News
·
May 08

Kelun-Biotech sac-TMT plus Keytruda NSCLC application accepted for review by China regulator

Reuters
·
May 08

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Nmpa Accepts New Indication Application for Sacituzumab Tirumotecan (Sac-TMT)

THOMSON REUTERS
·
May 08

3 Asian Stocks That May Be Undervalued In May 2026

Simply Wall St.
·
May 01

SKB BIO Shares Rise Nearly 3% in Late Trading as Three Studies Selected for Oral Presentation at 2026 ASCO Meeting

Stock News
·
Apr 24

Kelun-Biotech to present three studies in oral sessions at 2026 ASCO meeting

Reuters
·
Apr 22

Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 Asco Annual Meeting

THOMSON REUTERS
·
Apr 22

SKB BIO Updates Articles of Association: 233.19 Million-Share Structure, 11-Member Board and Cash-First Dividend Policy Confirmed

Bulletin Express
·
Apr 17

Kelun-Biotech converts 8.21 million Domestic and Unlisted Foreign shares; H-share free float lifts to 73.32%

Bulletin Express
·
Apr 17

SKB BIO-B Completes Full Circulation of H Shares

Stock News
·
Apr 17

Kelun-Biotech converts 8,214,278 shares into H shares for Hong Kong listing

Reuters
·
Apr 17